en · de · es · fr · pt
sr9009-notes.peptides9000.com › News › Analytical Detection And Stability — Field Notes

Analytical Detection And Stability — Field Notes

By Editorial Desk · published 2026-07-20 · last reviewed 2026-08-01 · News

A practical reference on circadian rhythm: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.

Analytical Detection and Stability

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

SR9009 Handling and Quality Control

Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.

SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.

SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.

Sr9009 at a glance

PropertyValueNotes
Common synonymsSR9009; StenabolicNickname is not a chemical name.
Typical analytical methodLC-MS/MSOften with isotope-labeled internal standard.
Storage temperature-20 °CDesiccated and protected from light.
Solution stabilityDMSO stock; avoid freeze-thawStore at -20 to -80 °C.
Regulatory statusNot approved; varies by countryMay be restricted as research chemical.

Mechanism and Preclinical Findings

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

Related pages on this site

Background and Mechanism of SR9009

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

SR9009 Background and Mechanism

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Background and Mechanism

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

Supporting material

A 15-hydroxyicosatetraenoate dehydrogenase metabolizes 15-hydroxyicosatetraenoic acid (i.e. 15(S)-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid or 15-HETE) to its 15-keto analog, 15-oxo-ETE, using NAD+ and NADH rather than NADP+ and NADPH as its co-factors. 15-Oxo-ETE appears to have a somewhat different spectrum of activities than its precursor, 15-HETE (see 15-Hydroxyicosatetraenoic acid

== Gameplay == Bloodlines is an action role-playing video game optionally presented from the first- or third-person perspective. Before the game begins, players create a male or female vampire character by selecting a vampire clan and configuring available points in three areas—Attributes, Abilities, and Disciplines (vampiric powers)—or by answering questions, which create a character for the player. The player can select one of seven vampire clans: the powerful Brujah, the decadent Toreador, the insane Malkavian, the aristocratic Ventrue, the monstrously deformed Nosferatu, the blood-magic-wielding Tremere, or the animalistic Gangrel. The player builds their character by spending acquired points to increase their ratings in the three areas. The points spent on Attributes and Abilities combine to determine a player's success or effectiveness in performing tasks such as using firearms, brawling, and lock-picking; for example, determining how accurate or how far the player can shoot or if they can hack a computer. Attributes are represented by physical (strength, dexterity, and stamina), social (charisma, manipulation, and appearance), and mental (perception, intelligence, and wits). Abilities are talents (such as brawling and dodging), skills (such as firearms and melee), and knowledge (such as computers and investigation). The player is initially assigned points to spend in the three areas, with the amount they can spend determined by clan; for example, the Brujah can spend the most points on physical and skill attributes.

== Brand names == The drug is marketed under various names globally Trelaglip (India, Zuventus Healthcare), ONETRELA (India,ALKEM LABS)Zafatek (Japan and China, Takeda Pharmaceuticals), Wedica and Triliptin (Bangladesh), Truli-1 (Kenya), Trelaget (Pakistan), and TRELA (Myanmar and Cambodia).

In April 2012, the Xinjiang Border Defense Corps Female Special Service team (新疆公安边防总队女子特勤分队) was founded. In March 2015 it was renamed to the "Snowy Eagle Female Special Service team" (雪鹰女子特勤分队) at the Xinjiang Border Corps Training Base. At its founding in 2012, it only had 6 members, and by March 2015 it had 34 members. It assisted in security at the China Eurasia Expo multiple times. The Shenzhen Border Defense Detachment operated the Maritime Special Service Team (Nicknamed "Maritime Jiaolongs"), a police tactical unit which is dedicated to maritime anti-terrorism, search and rescue, combat diving and VBSS.

Sources: en.wikipedia.org

Notes from published material

The documentation surrounding a spreadsheet containing a simple but "GxP" critical calculation should not match that of a Chromatography Data System with 20 Instruments) Determination of a "GxP critical" requirement for a computer system is subjective, and the definition needs to be tailored to the organisation involved. However, in general a "GxP" requirement may be considered to be a requirement which leads to the development/configuration of a computer function which has a direct impact on patient safety, the pharmaceutical product being processed, or has been developed/configured to meet a regulatory requirement. In addition if a function has a direct impact on GxP data (security or integrity) it may be considered "GxP critical".

Freeman also narrated The True Story of Glory Continues, a documentary about the 54th Massachusetts Infantry Regiment. In 1992, he appeared in Clint Eastwood's western Unforgiven, which won four Academy Awards including Best Picture. The film depicts William Munny (Eastwood), an aging outlaw and killer who takes on one more job with old friend Ned Logan (Freeman). Unforgiven was widely acclaimed, with one critic calling Freeman's performance "outstanding". Also in 1992 Freeman starred in the John G. Avildsen directed drama The Power of One acting opposite Stephen Dorf and John Gielgud in a loose adaptation of Bryce Courtenay's 1989 novel of the same name, in which he plays boxing coach Geel Piet. In 1993, Freeman made his directorial debut with the drama Bopha!, which tells the story of a black policeman (Danny Glover) during South Africa's apartheid era. Bopha! was well-received, in particular for Freeman's directing. Hal Hinson of The Washington Post wrote: "Freeman lays out the father-son dynamics with great skill and very little fuss. There's no hysteria in his approach; instead, he sticks to the facts, relying on his cast to provide the emotion. The result is a surprisingly powerful, insightful film." Kenneth Turan from Los Angeles Times also complimented Freeman's direction but thought the film was "more predictable than powerful". In 1994, Freeman portrayed Red, the redeemed convict in Frank Darabont's acclaimed drama The Shawshank Redemption, with co-star Tim Robbins. It is based on the 1982 Stephen King novella Rita Hayworth and the Shawshank Redemption.

=== Bejel === Bejel is caused by Treponema pallidum endemicum and is a disease that is endemic in hot and dry climates. The transmission path has not been fully mapped, however infections are thought to be transmitted via direct contact with lesion secretions or fomites rather than by sexual transmission. Bejel typically causes skin lesions, which first appear as small ulcers in the mouth, and secondary lesions that form in the oropharynx, or around the nipples of nursing women. Bejel can be treated with benzathine penicillin-G.

Sources: en.wikipedia.org

Further detail

== Detection == The first line of defense in preventing chronic Somogyi rebound is additional blood glucose testing. Continuous glucose monitoring is the preferred method to detect and prevent the Somogyi rebound, but this technology is far from universally used. Alternatively, testing blood sugar more often, 8 to 10 times daily with a traditional blood glucose meter, facilitates detecting the low blood sugar level before such a rebound occurs. Testing occasionally during the middle of the night is also important, particularly when high waking blood sugars are found, to determine if more insulin is needed to prevent hyperglycemia or if less insulin is needed to prevent such a rebound. Sometimes a person with diabetes will experience the Somogyi rebound when awake and notice symptoms of the initial low blood sugar or symptoms of the rebound. Waking with a night sweat (perhaps combined with a rapid heart rate) is a symptom of the adrenaline and rebound. Unfortunately, the evidence shows that patients with type 1 diabetes do not normally wake during nocturnal hypoglycemic episodes. While reviewing log data of blood glucose after the fact, signs of Somogyi rebound should be suspected when blood glucose numbers seem higher after the insulin dosage has been raised, particularly in the morning. One simple way to determine if nocturnal hypoglycemia may be causing morning hyperglycemia is to have the patient have a high protein snack with a small amount of carbohydrates at bedtime. This will help keep the blood sugar up overnight and prevent the Somogyi effect.

Systemic diseases may be associated with the development of periodontitis. It is thought that the host immune response to plaque is altered by the systemic condition. Hematological disorders associated with periodontitis include acquired neutropenia, leukemias and others. Genetic disorders potentially associated include familial and cyclic neutropenia, Down syndrome, leukocyte adhesion deficiency syndromes, Papillon–Lefèvre syndrome, Chédiak–Higashi syndrome, histiocytosis syndromes, glycogen storage disease, infantile genetic agranulocytosis, Cohen syndrome, Ehlers–Danlos syndrome (Types IV and VIII), hypophosphatasia, and others.

== Studies and research == A number of studies have been issued in regard to chocolate milk nutrition. A 2005 study by the New York City Department of Education found that by removing whole milk and replacing it with low-fat or fat-free chocolate milk, students were served an estimated 5,960 fewer calories and 619 fewer grams of fat per year. However, more recent studies show that fat-free and low-fat milk may actually increase body fat and contribute to obesity. Whole milk may in fact be healthier for obese children than low-fat or non-fat milk. An April 2007 study from Loughborough University indicated that low-fat milk was an effective rehydration drink. A November 2009 study conducted by scientists in Barcelona, Spain, suggests that regularly consuming skimmed milk with cocoa rich in flavonoids may reduce inflammation and slow or prevent the development of atherosclerosis. The study notes that its effects are not as pronounced as seen in consumption of red wine. However, in a single serving of cocoa, other researchers found 611 milligrams of gallic acid equivalents (GAE) and 564 milligrams of epicatechin equivalents (ECE), compared with 340 milligrams of GAE and 163 milligrams of ECE in red wine, and 165 milligrams of GAE and 47 milligrams of ECE in green tea. A study published in 2009 compared chocolate milk to a commercial recovery beverage (matched for carbohydrate and protein content) administered to cyclists after intense workouts.

==== New Zealand ==== This is known as creaming soda, ice cream soda, chill drink, or cream soda, though the flavor changes are negligible. It is usually a bright yellow colour or a white opaque. It is one of the many flavors sold by Foxton Fizz. It is also one of the many carbonated drink-flavors offered by Golden Circle.

Sources: en.wikipedia.org

Frequently asked questions

How is SR9009 measured in samples?

The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.

What storage conditions are typical for SR9009?

Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.

Is SR9009 legal to buy?

Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.

How is SR9009 detected in samples?

Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.

Network